Company intelligence / Profile preview

Philochem AG

Otelfingen, Zurich, Switzerlandphilochem.ch ↗

Ownership: Public · PHIL
Employees: ~25
Development stage: Phase 3

Overview

Several programs are in early clinical development. Notably:

PHC-102 for renal cell carcinoma in Phase I.
[68Ga]Ga-OncoFAP for solid tumors in Phase I.
Ga-OncoCAlX targeting CAIX for renal cell carcinoma at IND stage.
Ga-OncoACP3 targeting ACP3 for prostate cancer at IND stage.

Philogen group’s lead asset Onfekafusp alfa/L19TNF (“Fibromun”) is in a pivotal Phase III trial but this program belongs to the parent company rather than directly to Philochem.[1][5]

Therapeutic areas: Oncology
Modalities: Small moleculesAntibody-drug conjugatesRadiolabeled ligandsMonoclonal antibodiesPeptides
Industry: Biotech

Drug pipeline

9 assets

Ga-OncoFAP

8 more assets in the full pipeline.

Request access →

Partnerships

AbbVieBayerBristol Myers Squibb/CelgeneBoehringer IngelheimBraccoIBSAJanssen Biotech/Johnson & JohnsonMedImmune/AstraZenecaMerck Serono/MSD/Merck & Co.NovartisPfizerSchering AG/Bayer Healthcare Pharmaceuticals Inc.ServierSun Pharma[4]

Financials

Market cap: $4.7M
Total revenue: $0
Enterprise value: $11.1M

Beyond the preview

Go deeper on Philochem AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Philochem AG.

Explore the full profile